Claim 70% Off TipRanks Premium
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential
The latest update is out from Hyphens Pharma International Ltd. ( (SG:1J5) ).
Hyphens Pharma International has entered into a licensing, supply and commercialisation agreement granting Swiss company Louis Widmer SA the rights to market its patented Cerapro MED Skin Barrier Cream in six European countries, namely Switzerland, Liechtenstein, Austria, Belgium, Luxembourg and the Netherlands. Under the agreement, Hyphens Pharma will receive an upfront fee and ongoing royalties from sales, while positioning Cerapro—a CE-marked medical device approved for atopic dermatitis that lowers skin pH and helps restore the skin barrier—as a novel treatment option in major European markets, potentially expanding the product’s international footprint and strengthening the company’s presence in the dermatology segment.
More about Hyphens Pharma International Ltd.
Hyphens Pharma International Ltd. is a Singapore-based specialty pharmaceutical and consumer healthcare group that develops and commercialises innovative medical products, with a focus on dermatology and other niche therapeutic areas across international markets.
Average Trading Volume: 86,759
Technical Sentiment Signal: Buy
Current Market Cap: S$103.6M
For a thorough assessment of 1J5 stock, go to TipRanks’ Stock Analysis page.